Tamara Baumann, APRN
Women's Health · Reno, NVNPI 1326096017
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $6,080 of the $6,799 with a category attached, or 89.4%. Organon accounts for 61.9% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2021 at $4,984 and has fallen 99.2% since, to $38 in 2025. Among women's health clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 20 payments — averaging $339.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organon$4K
- Merck$2K
- Acella Pharmaceuticals, LLC$130
- Bayer$130
- Pfizer$38
- AbbVie$34
- plus $47 from 2 others
What the payments were for
- Speaking & faculty fees$6,08089%
- Travel & lodging$2083%
- Food & beverage$5118%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organon | 5 | $4,208 |
| Merck | 8 | $2,212 |
| Acella Pharmaceuticals, LLC | 1 | $130 |
| Bayer | 1 | $130 |
| Pfizer | 2 | $38 |
| AbbVie | 1 | $34 |
| Sanofi Pasteur Inc. | 1 | $28 |
| Gilead | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEXPLANON$6,288
- NP Thyroid 60$130
- Mirena$130
- Kyleena$130
- Skyla$130
How this compares
$6,799 in reported general payments places this provider in the 95th percentile of 36 women's health providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobetasol Propionate | 11 | $584 |
Paid to pharmacies, not to this prescriber.
Other women's health in Reno
- Katie BischoffReno$935
- Michelle MaysReno$923
- Ann MortaraReno$664
- Laurie SmithReno$544
- Allyson Stade PimplReno$303
- Carrissia FeasterReno$218
- Mackenzie RosetteReno$101
- Melanie HaggardReno$87
- Tari JustisReno$26
- Taylor GormanReno$6
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.